Thc Therapeutics Stock Buy Hold or Sell Recommendation
| THCT Stock | USD 0 0.0001 2.22% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding THC Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell THC Therapeutics given historical horizon and risk tolerance towards THC Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for THC Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out THC Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as THC and provide practical buy, sell, or hold advice based on investors' constraints. THC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
THC |
Execute THC Therapeutics Buy or Sell Advice
The THC recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on THC Therapeutics. Macroaxis does not own or have any residual interests in THC Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute THC Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
THC Therapeutics Trading Alerts and Improvement Suggestions
| THC Therapeutics is way too risky over 90 days horizon | |
| THC Therapeutics has some characteristics of a very speculative penny stock | |
| THC Therapeutics appears to be risky and price may revert if volatility continues | |
| THC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| THC Therapeutics currently holds 925.89 K in liabilities with Debt to Equity (D/E) ratio of 18.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. THC Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist THC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, THC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (1.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| THC Therapeutics currently holds about 3.82 K in cash with (388.48 K) of positive cash flow from operations. | |
| Roughly 31.0% of THC Therapeutics outstanding shares are owned by corporate insiders |
THC Therapeutics Returns Distribution Density
The distribution of THC Therapeutics' historical returns is an attempt to chart the uncertainty of THC Therapeutics' future price movements. The chart of the probability distribution of THC Therapeutics daily returns describes the distribution of returns around its average expected value. We use THC Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of THC Therapeutics returns is essential to provide solid investment advice for THC Therapeutics.
| Mean Return | 11.22 | Value At Risk | 0.00 | Potential Upside | 0.00 | Standard Deviation | 50.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of THC Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
THC Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to THC Therapeutics or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that THC Therapeutics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a THC pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 11.58 | |
β | Beta against Dow Jones | -3.02 | |
σ | Overall volatility | 100.76 | |
Ir | Information ratio | 0.11 |
THC Therapeutics Volatility Alert
THC Therapeutics is displaying above-average volatility over the selected time horizon. THC Therapeutics is a penny stock. Even though THC Therapeutics may be a good instrument to invest, many penny pink sheets are speculative instruments that are subject to artificial stock promotions. Please make sure you fully understand upside and downside scenarios of investing in THC Therapeutics or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings,sudden promotions and many other similar artificial hype indicators. We also encourage traders to check work history of company executives before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on THC instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.THC Therapeutics Fundamentals Vs Peers
Comparing THC Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze THC Therapeutics' direct or indirect competition across all of the common fundamentals between THC Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as THC Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of THC Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing THC Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare THC Therapeutics to competition |
| Fundamentals | THC Therapeutics | Peer Average |
| Return On Asset | -5.57 | -0.14 |
| Current Valuation | 1.57 M | 16.62 B |
| Shares Outstanding | 34.15 M | 571.82 M |
| Shares Owned By Insiders | 30.84 % | 10.09 % |
| Price To Earning | 1.25 X | 28.72 X |
| Price To Book | 46.07 X | 9.51 X |
| EBITDA | (1.06 M) | 3.9 B |
| Net Income | (1.89 M) | 570.98 M |
| Cash And Equivalents | 3.82 K | 2.7 B |
| Total Debt | 925.89 K | 5.32 B |
| Debt To Equity | 18.70 % | 48.70 % |
| Current Ratio | 0.01 X | 2.16 X |
| Book Value Per Share | (0.15) X | 1.93 K |
| Cash Flow From Operations | (388.48 K) | 971.22 M |
| Earnings Per Share | (0.09) X | 3.12 X |
| Number Of Employees | 1 | 18.84 K |
| Beta | 1.71 | -0.15 |
| Market Capitalization | 1.09 M | 19.03 B |
| Total Asset | 480.07 K | 29.47 B |
| Z Score | -6.0 | 8.72 |
| Net Asset | 480.07 K |
THC Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as THC . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 0.0046 | |||
| Day Typical Price | 0.0046 | |||
| Price Action Indicator | 1.0E-4 | |||
| Period Momentum Indicator | 1.0E-4 |
About THC Therapeutics Buy or Sell Advice
When is the right time to buy or sell THC Therapeutics? Buying financial instruments such as THC Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having THC Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.